Wedbush Downgrades Anthera Pharma (ANTH) to Neutral; Continued Progress in Clinical Trials is Encouraging but Valuation Suggests Limited NT Upside
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush downgraded Anthera Pharma (NASDAQ: ANTH) from Outperform to Neutral, price target lowered from $9 to $7.
Wedbush analyst says, "We are downgrading ANTH as our valuation suggests that additional upside may be fleeting in the near-term. Although the company has executed very well on progressing its late-stage clinical programs, we believe this success is largely reflected in the current stock price. Indeed, shares of ANTH have increased 92% since our initiation on 10/6/2010 (compared to an 11% rise in the S&P 500 index); and we are stepping to the sidelines in the wake of such a dramatic rise, particularly since we do not expect the next major milestone until Q2:2012."
For more ratings news on Anthera Pharma click here and for the rating history of Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.97 yesterday.
Wedbush analyst says, "We are downgrading ANTH as our valuation suggests that additional upside may be fleeting in the near-term. Although the company has executed very well on progressing its late-stage clinical programs, we believe this success is largely reflected in the current stock price. Indeed, shares of ANTH have increased 92% since our initiation on 10/6/2010 (compared to an 11% rise in the S&P 500 index); and we are stepping to the sidelines in the wake of such a dramatic rise, particularly since we do not expect the next major milestone until Q2:2012."
For more ratings news on Anthera Pharma click here and for the rating history of Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
- Berenberg Downgrades Inter Parfums (IPAR) to Hold
- Northcoast Downgrades Brinker Int'l (EAT) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
